- Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Listing Social Engagement Event
- Tevogen Bio Confirms Ongoing Efficacy of TVGN 489, Its Investigational Allogeneic Off-the-Shelf Immunotherapy, Against Dominant FLiRT Strains of SARS-CoV-2
- Tevogen Bio Reports First Quarter 2024 Financial Results
- Tevogen Bio Appoints Former Police Chief & FBI National Academy Graduate, William Keane, as Vice President of Strategic Initiatives
- Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational Objectives
- Tevogen Bio Announces Full Year 2023 Financial Results and Upcoming Operational Objectives
- Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments
- Tevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers
- Tevogen Bio Appoints Tapan V Shah as Head of Investor Relations and Corporate Development
- Tevogen Bio Reports Series A-1 Preferred Stock Investment at $10 Conversion Price
More ▼
Key statistics
As of last trade Tevogen Bio Holdings Inc (G28:DEU) traded at 0.685, 0.74% above its 52-week low of 0.68, set on May 23, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.705 |
---|---|
High | 0.705 |
Low | 0.685 |
Bid | 0.805 |
Offer | 0.835 |
Previous close | 0.685 |
Average volume | 0.00 |
---|---|
Shares outstanding | 166.11m |
Free float | 8.65m |
P/E (TTM) | -- |
Market cap | 134.14m USD |
EPS (TTM) | -0.0004 USD |
Data delayed at least 15 minutes, as of Jun 06 2024.
More ▼